282
2. Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell. 1992;68(4):799–808. doi:10.1016/0092-8674(92)90154-5.
3. Douniol M, Jacquette A, Cohen D, Bodeau N, Rachidi L, Angeard N, et al. Psychiatric and cognitive phenotype of childhood myotonic dystrophy type 1. Dev Med Child Neurol. 2012;54(10):905–911. doi:10.1111/j.1469-8749.2012.04379.x.
4. Emery AE. Population frequencies of inherited neuromuscular diseases: a world survey. Neuromuscul Disord. 1991;1(1):19–29. doi:10.1016/0960-8966(91)90039-U.
5. Hamel JI. Myotonic dystrophy. Continuum (Minneap Minn). 2022;28(6):1715–1734. doi:10.1212/CON.0000000000001184.
6. Harley HG, Brook JD, Rundle SA, Crow S, Reardon W, Buckler AJ, et al. Expansion of an unstable DNA region and phenotypic variation in myotonic dystrophy. Nature. 1992;355(6360):545–546. doi:10.1038/355545a0.
7. Horga A, Raja Rayan DL, Matthews E, Sud R, Fialho D, Durran SC, et al. Prevalence study of genetically defined skeletal muscle channelopathies in England. Neurology. 2013;80(16):1472–1475. doi:10.1212/WNL.0b013e31828cf8d0.
8. Jentsch TJ, Poët M, Fuhrmann JC, Zdebik AA. Physiological functions of CLC Cl⁻ channels gleaned from human genetic disease and mouse models. Annu Rev Physiol. 2005;67:779–807. doi:10.1146/annurev.physiol.67.032003.153245.
9. Johnson N, Imbrugia C, Dunn D, Duvall B, Butterfield R, Feldkamp M, et al. Genetic prevalence of myotonic dystrophy type 1. Neurology. 2019;92(15 Suppl):S23.003.
10. Johnson NE. Myotonic muscular dystrophies. Continuum (Minneap Minn). 2019;25(6):1682–1695. doi:10.1212/CON.0000000000000793.
11. Liao Q, Zhang Y, He J, Huang K. Global prevalence of myotonic dystrophy: an updated systematic review and meta-analysis. Neuroepidemiology. 2022;56(3):163–173. doi:10.1159/000524734.
12. Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W, Naylor SL, et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science. 2001;293(5531):864–867. doi:10.1126/science.1062125.
13. Mazon MJ, Barros F, De la Peña P, Quesada JF, Escudero A, Cobo AM, et al. Screening for mutations in Spanish families with myotonia: functional analysis of novel mutations in CLCN1 gene. Neuromuscul Disord. 2012;22(3):231–243. doi:10.1016/j.nmd.2011.10.013.
14. Meola G. Myotonic dystrophy type 2: the 2020 update. Acta Myol. 2020;39(4):222–234. doi:10.36185/2532-1900-026.
15. Musova Z, Mazanec R, Krepelova A, Ehler E, Vales J, Jaklova R, et al. Highly unstable sequence interruptions of the CTG repeat in the myotonic dystrophy gene. Am J Med Genet A. 2009;149A(7):1365–1374. doi:10.1002/ajmg.a.32987.
16. Orsini C, Petillo R, D'Ambrosio P, Ergoli M, Picillo E, Scutifero M, et al. CLCN1 molecular characterization in 19 South-Italian patients with dominant and recessive type of myotonia congenita. Front Neurol. 2020;11:63. doi:10.3389/fneur.2020.00063.
17. Öz Tunçer G, Sanri A, Aydin S, Hergüner ÖM, Özgün N, Kömür M, et al. Clinical and genetic spectrum of myotonia congenita in Turkish children. J Neuromuscul Dis. 2023;10(5):915–924. doi:10.3233/JND-230046.
18. Raja Rayan DL, Haworth A, Sud R, Matthews E, Fialho D, Burge J, et al. A new explanation for recessive myotonia congenita: exon deletions and duplications in CLCN1. Neurology. 2012;78(24):1953–1958. doi:10.1212/WNL.0b013e318259e19c.
19. Sasaki R, Nakaza M, Furuta M, Fujino H, Kubota T, Takahashi MP. Mutation spectrum and health status in skeletal muscle channelopathies in Japan. Neuromuscul Disord. 2020;30(7):546–553. doi:10.1016/j.nmd.2020.06.001.
20. Thornton CA. Myotonic dystrophy. Neurol Clin. 2014;32(3):705–719. doi:10.1016/j.ncl.2014.04.011.
21. Todd PK, Paulson HL. RNA-mediated neurodegeneration in repeat expansion disorders. Ann Neurol. 2010;67(3):291–300. doi:10.1002/ana.21948.
22. Topaloglu H. Epidemiology of muscular dystrophies in the Mediterranean area. Acta Myol. 2013;32(3):138–141.
23. Turner C, Hilton-Jones D. Myotonic dystrophy: diagnosis, management and new therapies. Curr Opin Neurol. 2014;27(5):599–606. doi:10.1097/WCO.0000000000000128.
24. Udd B, Krahe R. The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol. 2012;11(10):891–905. doi:10.1016/S1474-4422(12)70204-8.
25. Udd B, Meola G, Krahe R, Thornton C, Ranum L, Day J, et al. Report of the 115th ENMC workshop: DM2/PROMM and other myotonic dystrophies. Neuromuscul Disord. 2003;13(7–8):589–596. doi:10.1016/S0960-8966(03)00092-0.
26. Yotova V, Labuda D, Zietkiewicz E, Gehl D, Lovell A, Lefebvre JF, et al. Anatomy of a founder effect: myotonic dystrophy in Northeastern Quebec. Hum Genet. 2005;117(2–3):177–187. doi:10.1007/s00439-005-1298-8.